April 4 (Reuters) - Johnson & Johnson JNJ.N:
TREMFYA® (GUSELKUMAB) IS THE FIRST AND ONLY IL-23 INHIBITOR TO SIGNIFICANTLY REDUCE BOTH THE SIGNS AND SYMPTOMS AND THE PROGRESSION OF STRUCTURAL DAMAGE IN ADULTS LIVING WITH ACTIVE PSORIATIC ARTHRITIS
JOHNSON & JOHNSON - TREMFYA PHASE 3B STUDY ACHIEVES PRIMARY AND SECONDARY ENDPOINTS
JOHNSON & JOHNSON - TREMFYA SAFETY PROFILE CONSISTENT WITH NO NEW SAFETY SIGNALS
JOHNSON & JOHNSON - TREMFYA SHOWS LESS STRUCTURAL DAMAGE PROGRESSION AT WEEK 24
Source text: ID:nPn70mvxba
Further company coverage: JNJ.N
(((( Reuters.briefs@thomsonreuters.com ;));))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。